
Dr. Eduardo Marban | Executive Director, Smidt Heart Institute @CedarsSinai Views are my own, not institutional policy!
Cedars-Sinai Medical Center
Joined May 2021
- Tweets1.4K
- Following381
- Followers2K
- Likes6.2K
Eduardo Marban, MD, PhD retweeted
Please take a minute to read what Dr. Cassidy, DMD patient & patient representative for Capricor’s Adcom, wrote about the upcoming FDA decision on deramiocel. I believe his opinion on the matter carries significant weight considering he went back and forth with regulators, not just recently, but many times in the past regarding other drugs for DMD.
The DMD is loudly calling for the approval of deramiocel. We HOPE to see it approved soon, @FDA @FDADrugs @FDA_KyleD!
Real treat at today’s lab meeting. Superstar Asst Prof Alessandra Ciullo @AleCiulloPhD presented her innovative work on #exomer therapy (one of our novel #ncRNA drugs) for #Freidreich’s #ataxia, a triplet repeat genetic disorder affecting both the #cerebellum (causing shakes and postural instability) and the heart (lethal #cardiomyopathy). First demonstration of exomer efficacy in a #mitochondrial disease! 👍👏
Rigorous studies of deramiocel’s efficacy in @Duchenne @cardiomyopathy. Strong evidence of disease-modifying bioactivity in advanced @DMD, especially in the prespecified subgroup of HOPE-3 subjects with cardiomyopathy at baseline. Progression totally halted over one year of follow-up, with a trend towards net improvement— contrary to the relentless progression of dysfunction and scar in the placebo group. Congrats Jon Soslow, Chet Vila and team!
This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible.
Read the press release: bit.ly/4BMIYM5
#AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR
This week's lab meeting featured @junlangli discussing his pioneering work on a new #exomer derived from #iPSC extracellular vesicles. Terrific discussion about mechanism and clinical implications!
Eduardo Marban, MD, PhD retweeted
Dusty has always loved figuring out how things work. When he could no longer fly his drone, he designed a controller he could use. Here he tells his story —including what it felt like to fly again.
#duchenne #innovation #limitless
musculardystrophynews.com/gu…
.@FDA has proclaimed their innovative, proactive approach to rare diseases, but will they deliver? By any measure, #deramiocel exceeds the typical burden of evidence for efficacy and safety in a rare disease, with no less than 5 positive clinical trials. But FDA has yet to approve this novel cell therapy for #Duchenne muscular dystrophy. Meanwhile, boys and young men with advanced #DMD—precisely those who stand to benefit most from deramiocel—are awaiting this potentially transformational therapy. It’s time for FDA to do more than talk about rare diseases! The 28 authors of our recent @TheLancet HOPE-3 paper wrote the attached letter making these points to @FDA-- have a look!
Link for full letter lnkd.in/p/gptcbDKX
Eduardo Marban, MD, PhD retweeted
Dr. Craig McDonald and the other 28 physician-scientists/investigators in HOPE-3 have spoken! @FDA trust the expert DMD physicians who work with us patients the most.
Approve Deramiocel! $CAPR
Read the full letter on Dr. McDonald’s LinkedIn by clicking this link: lnkd.in/p/gBMSkKUS
🙏 Junlang for the opportunity to highlight your work on a new #exomer!
Really enjoyed @MarbanLab's talk yesterday! Always inspiring to hear him bring our work together and put it into a bigger picture! Especially when you get to see your own data on the big screen! 😎🫀 #exomer
Eduardo Marban, MD, PhD retweeted
An elegant talk by @MarbanLab at Grand Rounds on novel RNA drugs #exomers and our long, winding, and fun research arc. To the clinic or bust!
Eduardo Marban, MD, PhD retweeted
Tune in on Tuesday, Oct 20th at 8 am PDT to hear the latest updates on our work with #exomers
Microsoft Teams meeting
Join: teams.microsoft.com/meet/212…
Meeting ID: 212 993 917 099 964
Passcode: i8iF9Rb7
Tune in on Tuesday, Oct 20th at 8 am PDT to hear the latest updates on our work with #exomers
Microsoft Teams meeting
Join: teams.microsoft.com/meet/212…
Meeting ID: 212 993 917 099 964
Passcode: i8iF9Rb7
This week’s #journalclub featured @T_Ikenouchi on modulators of #cardiomyocyte proliferation (yes, there are even more lurking out there), @AleCiulloPhD on cell-cell #mitochondrial transfer in #FreidreichsAtaxia (who’d have thought it happens frequently enough to make a therapeutic difference?), and me discussing a phase 1 trial of an anti-RAGE #siRNA for #asthma (nice template for our own upcoming FIH #exomer trials).
Terrific lab meeting this week by @ke_liaoPhD on the mechanism of #depression, which afflicts one third of patients after a #HeartAttack. Amazing discoveries involving #EVs, circular #RNA and depletion of miRs. We even have a prototype therapeutic candidate! Exciting times…
Late Breaking clinical trial #HOPE-3 OLE shows striking benefits of #deramiocel sustained over two years of therapy, and 76% slowing of #Duchenne myopathy progression in those who crossed over from placebo to deramiocel after one year. Work of ace #DMD trialist Craig McDonald highlighted at the @WorldMuscleSoc meeting in Hiroshima. Trial sponsored by @Capricor based on intellectual property from my team at Cedars-Sinai.
Enjoyed my visit to @dgsomucla and the opportunity to discuss #exomers for #scleroderma, #Duchenne and #arrythmogenic #cardiomyopathy
@TheIbrahimLab @AleCiulloPhD @rrogerslab @EugenioCingolan @soussi_salwa @XMichaelJonesMD
Delighted to have @MarbanLab for an inspiring talk on translating cardiosphere-derived cell biology into RNA therapeutics. Fascinating insights into extracellular vesicles, Y RNA, macrophage reprogramming, tissue repair, and TY1; from discovery to clinical translation. #UCLA
Looking forward to sharing our work on #exomers with friends and colleagues at @dgsomucla next week!
Proud of my two former trainees (the poster, Eugenio, and the speaker, Tetsuo)!!
Fantastic lecture on #AF by Prof Tetsuo Sasano from Tokyo Institute of Science 🇯🇵 @CedarsSinaiMed - from basic mechanisms to improving detection on a #taxiride 🚕 or #hotelbed 🏨 CedarsSinai @APHRSOfficial @HRSonline
1
21
1,366
Eduardo Marban, MD, PhD retweeted
Suggesting a novel therapy for #SystemicSclerosis: doi.org/10.1172/jci.insight.…
Eduardo Marbán & team @Marbanlab @CedarsSinai report that an orally delivered noncoding RNA (TY1) reduces inflammation and organ fibrosis in models of systemic sclerosis through inhibition of the cGAS/STING axis. The authors employed in vitro and in vivo models and evaluated skin, lung, and heart.
The video shows TY1 treatment in preclinical models of systemic sclerosis.
@AleCiulloPhD @TheIbrahimlab @the_asci
Eduardo Marban, MD, PhD retweeted
Noncoding RNA TY1 reverses fibrosis in systemic sclerosis by attenuating the cGAS/STING pathway @JCI_insight @MarbanLab
insight.jci.org/articles/vie…

















































